MedTrace Logo

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

NCT03192943 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-04-01

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors

Conditions

Interventions

DRUG

BMS-986205

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified day

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-23
Primary Completion
2018-12-11
Completion
2018-12-11
FDA Drug
Yes

Countries

  • Japan

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03192943 on ClinicalTrials.gov